Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Cancer immunotherapies targeting immune checkpoints such as programmed cell-death protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are revolutionizing cancer treatment and transforming the practice of medical oncology. However, despite all the recent successes of this type o...

Full description

Bibliographic Details
Main Authors: Luisa Chocarro de Erauso, Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Carlos Hernandez, Gonzalo Fernandez, Maria Jesus Garcia-Granda, Ester Blanco, Ruth Vera, Grazyna Kochan, David Escors
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Pharmacology
Subjects:
immune checkpoint blockade
programmed cell-death protein 1
programmed cell-death 1 ligand 1
immunotherapy
tumor-intrinsic resistance
tumor-extrinsic resistance
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00441/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.00441/full

Similar Items